Lilly victorious in Alimta patent case
Eli Lilly has welcomed a decision by the UK Supreme Court that alternative salt forms of its cancer drug Alimta, marketed by Teva’s Actavis, directly infringe on its vitamin regimen patents in the UK, France, Spain and Italy, overturning previous High Court and Court of Appeal judgements.
Read More
